|
JPH11507052A
(ja)
*
|
1995-06-07 |
1999-06-22 |
スージェン・インコーポレーテッド |
キナゾリンおよび医薬組成物
|
|
US6906093B2
(en)
|
1995-06-07 |
2005-06-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
|
US6316635B1
(en)
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
|
US6147106A
(en)
*
|
1997-08-20 |
2000-11-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
US6696448B2
(en)
|
1996-06-05 |
2004-02-24 |
Sugen, Inc. |
3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
|
|
EP1014953B1
(en)
|
1997-03-05 |
2012-04-25 |
Sugen, Inc. |
Formulations for hydrophobic pharmaceutical agents
|
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
|
US6316429B1
(en)
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
|
US6486185B1
(en)
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
|
US6316479B1
(en)
|
1997-05-19 |
2001-11-13 |
Sugen, Inc. |
Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
|
|
US6987113B2
(en)
|
1997-06-11 |
2006-01-17 |
Sugen, Inc. |
Tyrosine kinase inhibitors
|
|
US6051593A
(en)
|
1997-06-20 |
2000-04-18 |
Sugen, Inc. |
3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
|
|
US6114371A
(en)
*
|
1997-06-20 |
2000-09-05 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
|
US6313158B1
(en)
|
1997-06-20 |
2001-11-06 |
Sugen, Inc. |
Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
|
|
US6130238A
(en)
*
|
1997-06-20 |
2000-10-10 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
|
US6133305A
(en)
|
1997-09-26 |
2000-10-17 |
Sugen, Inc. |
3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
|
|
US6531502B1
(en)
|
1998-01-21 |
2003-03-11 |
Sugen, Inc. |
3-Methylidenyl-2-indolinone modulators of protein kinase
|
|
US6514981B1
(en)
|
1998-04-02 |
2003-02-04 |
Sugen, Inc. |
Methods of modulating tyrosine protein kinase function with indolinone compounds
|
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
|
KR100743287B1
(ko)
|
1998-05-29 |
2007-07-26 |
수젠, 인크. |
피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제
|
|
US6153634A
(en)
|
1998-12-17 |
2000-11-28 |
Hoffmann-La Roche Inc. |
4,5-azolo-oxindoles
|
|
DE69906152T2
(de)
|
1998-12-17 |
2004-02-12 |
F. Hoffmann-La Roche Ag |
4-alkenyl (und alkinyl)oxoindole als inhibitoren cyclinabhängiger kinasen, insbesondere cdk2
|
|
KR20010101266A
(ko)
|
1998-12-17 |
2001-11-14 |
프리돌린 클라우스너, 롤란드 비. 보레르 |
Jnk 단백질 키나제의 억제제로서의 4-아릴옥신돌
|
|
ES2301255T3
(es)
*
|
1998-12-17 |
2008-06-16 |
F. Hoffmann-La Roche Ag |
4,5-pirazinaxindoles como inhibidores de proteinoquinasas.
|
|
GB9904932D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
|
|
US7064114B2
(en)
|
1999-03-19 |
2006-06-20 |
Parker Hughes Institute |
Gel-microemulsion formulations
|
|
US6689806B1
(en)
|
1999-03-24 |
2004-02-10 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
|
AU3770000A
(en)
*
|
1999-03-24 |
2000-10-09 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
|
JP2000281588A
(ja)
*
|
1999-03-30 |
2000-10-10 |
Sankyo Co Ltd |
ガンの予防又は治療薬及びそのスクリーニング方法
|
|
AU4556800A
(en)
*
|
1999-04-27 |
2000-11-10 |
Smithkline Beecham Plc |
Novel treatment
|
|
US6407101B1
(en)
|
1999-05-04 |
2002-06-18 |
American Home Products Corporation |
Cyanopyrroles
|
|
US6380178B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Cyclic regimens using cyclocarbamate and cyclic amide derivatives
|
|
US6444668B1
(en)
|
1999-05-04 |
2002-09-03 |
Wyeth |
Combination regimens using progesterone receptor modulators
|
|
US6339098B1
(en)
|
1999-05-04 |
2002-01-15 |
American Home Products Corporation |
2,1-benzisothiazoline 2,2-dioxides
|
|
US6329416B1
(en)
|
1999-05-04 |
2001-12-11 |
American Home Products Corporation |
Combination regimens using 3,3-substituted indoline derivatives
|
|
US6417214B1
(en)
|
1999-05-04 |
2002-07-09 |
Wyeth |
3,3-substituted indoline derivatives
|
|
US6380235B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Benzimidazolones and analogues
|
|
US6462032B1
(en)
|
1999-05-04 |
2002-10-08 |
Wyeth |
Cyclic regimens utilizing indoline derivatives
|
|
US6355648B1
(en)
|
1999-05-04 |
2002-03-12 |
American Home Products Corporation |
Thio-oxindole derivatives
|
|
US6399593B1
(en)
|
1999-05-04 |
2002-06-04 |
Wyeth |
Cyclic regimens using cyclic urea and cyclic amide derivatives
|
|
US6319912B1
(en)
|
1999-05-04 |
2001-11-20 |
American Home Products Corporation |
Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
|
|
US6498154B1
(en)
|
1999-05-04 |
2002-12-24 |
Wyeth |
Cyclic regimens using quinazolinone and benzoxazine derivatives
|
|
US6306851B1
(en)
|
1999-05-04 |
2001-10-23 |
American Home Products Corporation |
Cyclocarbamate and cyclic amide derivatives
|
|
US6423699B1
(en)
|
1999-05-04 |
2002-07-23 |
American Home Products Corporation |
Combination therapies using benzimidazolones
|
|
US6509334B1
(en)
|
1999-05-04 |
2003-01-21 |
American Home Products Corporation |
Cyclocarbamate derivatives as progesterone receptor modulators
|
|
US6358947B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Tetracyclic progesterone receptor modulator compounds and methods
|
|
US6391907B1
(en)
|
1999-05-04 |
2002-05-21 |
American Home Products Corporation |
Indoline derivatives
|
|
US6358948B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
|
|
US6369056B1
(en)
|
1999-05-04 |
2002-04-09 |
American Home Products Corporation |
Cyclic urea and cyclic amide derivatives
|
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
|
US6313310B1
(en)
|
1999-12-15 |
2001-11-06 |
Hoffmann-La Roche Inc. |
4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
|
|
CA2395461C
(en)
|
1999-12-22 |
2010-05-25 |
Sugen, Inc. |
Methods of modulating c-kit tyrosine kinase function with indolinone compounds
|
|
US6339100B1
(en)
|
1999-12-29 |
2002-01-15 |
The Trustees Of Columbia University In The City Of New York |
Methods for inhibiting mastocytosis
|
|
EP1207864A2
(en)
*
|
2000-02-05 |
2002-05-29 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of erk
|
|
HRP20020751B1
(hr)
|
2000-02-15 |
2011-01-31 |
Sugen |
Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
|
|
US6620818B1
(en)
|
2000-03-01 |
2003-09-16 |
Smithkline Beecham Corporation |
Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
|
|
UA73119C2
(en)
|
2000-04-19 |
2005-06-15 |
American Home Products Corpoir |
Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
|
|
MY128449A
(en)
|
2000-05-24 |
2007-02-28 |
Sugen Inc |
Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
|
JP2003535847A
(ja)
|
2000-06-02 |
2003-12-02 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ/ホスファターゼ阻害剤としてのインドリノン誘導体
|
|
GB0016454D0
(en)
|
2000-07-04 |
2000-08-23 |
Hoffmann La Roche |
Thienopyrrolidinones
|
|
CA2417500C
(en)
*
|
2000-07-28 |
2008-11-18 |
Georgetown University Medical Center |
Erbb-2 selective small molecule kinase inhibitors
|
|
ES2230337T3
(es)
|
2000-09-01 |
2005-05-01 |
Glaxo Group Limited |
Derivados de oxindol.
|
|
US6638965B2
(en)
|
2000-11-01 |
2003-10-28 |
Boehringer Ingelheim Pharma Kg |
Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
|
|
DE10054019A1
(de)
*
|
2000-11-01 |
2002-05-23 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
|
EP1488809A1
(en)
|
2001-01-16 |
2004-12-22 |
Glaxo Group Limited |
Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
|
|
AR042586A1
(es)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
|
WO2002070478A1
(en)
|
2001-03-06 |
2002-09-12 |
Astrazeneca Ab |
Indolone derivatives having vascular-damaging activity
|
|
WO2002096361A2
(en)
|
2001-05-30 |
2002-12-05 |
Sugen, Inc. |
5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
|
DE10134196B4
(de)
*
|
2001-07-13 |
2005-08-18 |
Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt |
Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
|
|
US7015231B2
(en)
*
|
2001-09-27 |
2006-03-21 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
|
US20030119839A1
(en)
*
|
2001-12-13 |
2003-06-26 |
Nan-Horng Lin |
Protein kinase inhibitors
|
|
GB0206861D0
(en)
*
|
2002-03-22 |
2002-05-01 |
Glaxo Group Ltd |
Medicaments
|
|
BR0308985A
(pt)
*
|
2002-04-03 |
2005-01-04 |
Allergan Inc |
(3z)-3-(3-hidro-isobenzofuran-1-ilideno)-1,3-diidro-2h-i ndol-2-onas como inibidores da cinase
|
|
US6541504B1
(en)
*
|
2002-04-03 |
2003-04-01 |
Allergan Sales, Llc |
(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
|
AU2003221684A1
(en)
*
|
2002-04-08 |
2003-10-27 |
Smithkline Beecham Corporation |
Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
|
|
US7514468B2
(en)
|
2002-07-23 |
2009-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
|
|
ITMI20021620A1
(it)
*
|
2002-07-23 |
2004-01-23 |
Novuspharma Spa |
Composto ad ativita' antitumorale
|
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
|
AU2003250701A1
(en)
*
|
2002-07-31 |
2004-02-16 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
|
EP2573079A3
(en)
*
|
2002-08-23 |
2015-03-11 |
Novartis AG |
Benzimidazole quinolinones and uses thereof
|
|
US7825132B2
(en)
*
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
|
US8673924B2
(en)
|
2002-09-04 |
2014-03-18 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
|
US8580782B2
(en)
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
|
RU2380369C9
(ru)
|
2002-09-04 |
2011-07-10 |
Шеринг Корпорейшн |
Новые пиразолопиримидины как ингибиторы циклин-зависимой киназы
|
|
CA2542007C
(en)
*
|
2002-10-09 |
2010-06-29 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
|
SG148864A1
(en)
*
|
2002-11-13 |
2009-01-29 |
Chiron Corp |
Methods of treating cancer and related methods
|
|
AU2003302665B2
(en)
*
|
2002-11-15 |
2009-12-24 |
Symphony Evolution, Inc. |
Kinase modulators
|
|
US20050019366A1
(en)
*
|
2002-12-31 |
2005-01-27 |
Zeldis Jerome B. |
Drug-coated stents and methods of use therefor
|
|
WO2004064733A2
(en)
*
|
2003-01-15 |
2004-08-05 |
Board Of Regents, University Of Texas System |
The use of c-raf inhibitors for the treatment of neurodegenerative diseases
|
|
RU2365373C2
(ru)
|
2003-05-27 |
2009-08-27 |
Роберт Пер Хэгерквист |
Применение ингибитора тирозинкиназы для лечения диабета
|
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
|
EP1682126B1
(en)
*
|
2003-10-16 |
2009-07-01 |
Novartis Vaccines and Diagnostics, Inc. |
Substituted benzazoles and use thereof as inhibitors of raf kinase
|
|
JP4823914B2
(ja)
*
|
2003-11-07 |
2011-11-24 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
Fgfr3の阻害および多発性骨髄腫の治療
|
|
WO2005068424A1
(en)
*
|
2004-01-20 |
2005-07-28 |
Cell Therapeutics Europe S.R.L. |
Indolinone derivatives as receptor tyrosine kinase ihibitors
|
|
WO2005080392A1
(ja)
*
|
2004-02-19 |
2005-09-01 |
Takeda Pharmaceutical Company Limited |
ピラゾロキノロン誘導体およびその用途
|
|
EP1718306A2
(en)
*
|
2004-02-20 |
2006-11-08 |
Chiron Corporation |
Modulation of inflammatory and metastatic processes
|
|
DE102004012070A1
(de)
*
|
2004-03-12 |
2005-09-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
|
|
US7759383B2
(en)
|
2005-02-22 |
2010-07-20 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of MDM2 and the uses thereof
|
|
AU2006247803B2
(en)
*
|
2005-05-13 |
2011-12-22 |
Novartis Ag |
Methods for treating drug resistant cancer
|
|
EP2270000B1
(en)
|
2005-05-23 |
2015-07-29 |
Novartis AG |
Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
|
|
PE20070335A1
(es)
*
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
|
KR20080074143A
(ko)
*
|
2005-11-29 |
2008-08-12 |
노파르티스 아게 |
퀴놀리논 제제
|
|
US8546404B2
(en)
|
2005-12-13 |
2013-10-01 |
Merck Sharp & Dohme |
Compounds that are ERK inhibitors
|
|
JP2009528280A
(ja)
|
2006-02-16 |
2009-08-06 |
シェーリング コーポレイション |
Erkインヒビターとしてのピロリジン誘導体
|
|
BRPI0715423A2
(pt)
*
|
2006-07-21 |
2013-07-02 |
Novartis Ag |
formulaÇÕes para Éteres de benzimidazolil piridila
|
|
EP2074226A2
(en)
*
|
2006-09-19 |
2009-07-01 |
Novartis AG |
Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
|
|
WO2008083491A1
(en)
|
2007-01-11 |
2008-07-17 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of cancer
|
|
KR100799821B1
(ko)
*
|
2007-02-05 |
2008-01-31 |
동화약품공업주식회사 |
신규한 이마티닙 캠실레이트 및 그의 제조방법
|
|
UY30892A1
(es)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
|
UY30915A1
(es)
|
2007-02-16 |
2008-09-02 |
Smithkline Beecham Corp |
Método de tratamiento de canceres
|
|
US20110160130A1
(en)
*
|
2007-02-16 |
2011-06-30 |
Connie Erickson-Miller |
Cancer treatment method
|
|
US20110129550A1
(en)
|
2007-02-16 |
2011-06-02 |
Connie Erickson-Miller |
Cancer treatment method
|
|
WO2008134124A1
(en)
*
|
2007-04-30 |
2008-11-06 |
The Uab Research Foundation |
Ul97 inhibitors for treatment of proliferative disorders
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
JP5352476B2
(ja)
|
2007-06-05 |
2013-11-27 |
武田薬品工業株式会社 |
キナーゼ阻害剤としての二環式複素環化合物
|
|
JP5270553B2
(ja)
|
2007-08-23 |
2013-08-21 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
|
EP2184285B1
(en)
|
2007-08-29 |
2015-11-04 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
|
CA2736177A1
(en)
|
2007-09-06 |
2009-03-12 |
Boston Biomedical, Inc. |
Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
|
|
KR101530402B1
(ko)
*
|
2007-10-09 |
2015-06-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
급성 인간 골수성 백혈병 세포를 죽이는 트롬보포이에틴 수용체 효능제 (tpora)
|
|
EP2235004A4
(en)
|
2007-12-21 |
2011-05-04 |
Univ Health Network |
INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
|
|
US8466151B2
(en)
*
|
2007-12-26 |
2013-06-18 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
|
CN102015693B
(zh)
|
2008-02-21 |
2014-10-29 |
默沙东公司 |
作为erk抑制剂的化合物
|
|
EP3023426A1
(en)
|
2008-07-17 |
2016-05-25 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
|
AR074199A1
(es)
|
2008-11-20 |
2010-12-29 |
Glaxosmithkline Llc |
Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
|
|
EP2399921B1
(en)
|
2008-12-01 |
2015-08-12 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
|
UY32306A
(es)
|
2008-12-09 |
2010-07-30 |
Gilead Sciences Inc |
Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
|
|
NZ594064A
(en)
|
2009-01-30 |
2012-08-31 |
Glaxosmithkline Llc |
Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
|
|
WO2010100127A1
(en)
|
2009-03-04 |
2010-09-10 |
Novartis Ag |
Disubstituted imidazole derivatives as modulators of raf kinase
|
|
WO2010115279A1
(en)
|
2009-04-06 |
2010-10-14 |
University Health Network |
Kinase inhibitors and method of treating cancer with same
|
|
ES2638323T3
(es)
|
2009-05-20 |
2017-10-19 |
Glaxosmithkline Llc |
Derivados de tiazolopirimidinona como inhibidores de PI3 quinasa
|
|
UA111579C2
(uk)
|
2009-08-17 |
2016-05-25 |
Інтеллікіне Ллк |
ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
|
|
EA027959B1
(ru)
|
2009-08-21 |
2017-09-29 |
Смитклайн Бичем (Корк) Лтд. |
Способ лечения рака с помощью лапатиниба
|
|
WO2011025859A1
(en)
|
2009-08-26 |
2011-03-03 |
Cylene Pharmaceuticals, Inc. |
Condensed quinolines as protein kinase modulators
|
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
WO2011031965A1
(en)
|
2009-09-14 |
2011-03-17 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
|
HUE060206T2
(hu)
|
2009-10-16 |
2023-02-28 |
Novartis Ag |
MEK gátlót és B-Raf gátlót tartalmazó kombináció
|
|
BR112012009329A2
(pt)
|
2009-10-22 |
2016-06-07 |
Gilead Sciences Inc |
derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia)
|
|
US20150018301A1
(en)
*
|
2009-11-06 |
2015-01-15 |
The Johns Hopkins University |
LRRK-2-Mediated Neuronal Toxicity
|
|
WO2011097526A1
(en)
|
2010-02-05 |
2011-08-11 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
US8598156B2
(en)
|
2010-03-25 |
2013-12-03 |
Glaxosmithkline Llc |
Chemical compounds
|
|
WO2011120153A1
(en)
|
2010-04-01 |
2011-10-06 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
|
TWI516262B
(zh)
|
2010-04-06 |
2016-01-11 |
健康網路大學 |
激酶抑制劑及以其治療癌症的方法
|
|
BR112012032884A2
(pt)
|
2010-06-25 |
2016-11-08 |
Novartis Ag |
compostos e composições heteroarílicos como inibidores de quinase proteica
|
|
WO2012036919A2
(en)
|
2010-09-14 |
2012-03-22 |
Glaxosmithkline Llc |
Combination of braf and vegf inhibitors
|
|
KR101594002B1
(ko)
|
2010-10-06 |
2016-02-15 |
글락소스미스클라인 엘엘씨 |
Pi3 키나제 억제제로서의 벤즈이미다졸 유도체
|
|
GB201112607D0
(en)
|
2011-07-22 |
2011-09-07 |
Glaxo Group Ltd |
Novel compounds
|
|
TWI505828B
(zh)
|
2010-12-20 |
2015-11-01 |
葛蘭素史克智慧財產(第二)有限公司 |
新穎醫藥組成物
|
|
BR112013017722A2
(pt)
|
2011-01-11 |
2016-07-12 |
Glaxosmithkline Llc |
combinação
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
JP6150813B2
(ja)
|
2011-11-11 |
2017-06-21 |
ノバルティス アーゲー |
増殖性疾患の治療方法
|
|
CA2856406C
(en)
|
2011-11-23 |
2020-06-23 |
Novartis Ag |
Pharmaceutical formulations
|
|
BR112014019034A8
(pt)
|
2012-01-31 |
2017-07-11 |
Smithkline Beecham Cork Ltd |
Método para tratamento de câncer
|
|
WO2013143597A1
(en)
|
2012-03-29 |
2013-10-03 |
Glaxo Group Limited |
Demethylase enzymes inhibitors
|
|
EP3181564B1
(en)
|
2012-11-20 |
2019-09-18 |
H. Hoffnabb-La Roche Ag |
Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
|
|
PE20151024A1
(es)
|
2012-11-30 |
2015-07-27 |
Glaxosmithkline Llc |
Composicion farmaceutica novedosa
|
|
US20150342957A1
(en)
|
2013-01-09 |
2015-12-03 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination
|
|
WO2014108858A1
(en)
|
2013-01-10 |
2014-07-17 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Fatty acid synthase inhibitors
|
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
|
JP6378308B2
(ja)
*
|
2013-03-13 |
2018-08-22 |
ボストン バイオメディカル, インコーポレイテッド |
がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体
|
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
HK1219421A1
(zh)
|
2013-03-15 |
2017-04-07 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
|
AU2014276440A1
(en)
|
2013-06-03 |
2015-11-05 |
Novartis Ag |
Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor
|
|
WO2014210354A1
(en)
|
2013-06-28 |
2014-12-31 |
Genentech, Inc. |
Azaindazole compounds as inhibitors of t790m containing egfr mutants
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
MX2016004267A
(es)
|
2013-10-01 |
2016-07-08 |
Novartis Ag |
Combinacion.
|
|
CA2923899A1
(en)
|
2013-10-01 |
2015-04-09 |
Novartis Ag |
Enzalutamide in combination with afuresertib for the treatment of cancer
|
|
WO2015056180A1
(en)
|
2013-10-15 |
2015-04-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Indoline derivatives as inhibitors of perk
|
|
EA030089B1
(ru)
|
2013-10-18 |
2018-06-29 |
Юниверсити Хелс Нетуорк |
Лечение рака поджелудочной железы
|
|
BR112016011222A2
(pt)
|
2013-12-12 |
2017-09-19 |
Novartis Ag |
Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer
|
|
US20160361309A1
(en)
|
2014-02-26 |
2016-12-15 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer patients responding to ezh2 inhibitor gsk126
|
|
CN106456642A
(zh)
|
2014-03-12 |
2017-02-22 |
诺华股份有限公司 |
含btk抑制剂与akt抑制剂的组合
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2016001907A1
(en)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
|
|
SI3166607T1
(sl)
|
2014-07-11 |
2023-01-31 |
Gilead Sciences, Inc. |
Modulatorji toličnih receptorjev za zdravljenje HIV-a
|
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
|
CN110305133A
(zh)
|
2014-09-16 |
2019-10-08 |
吉利德科学公司 |
Toll样受体调节剂的固体形式
|
|
WO2016055935A1
(en)
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
AU2016303550B2
(en)
|
2015-08-04 |
2019-06-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
WO2017021911A1
(en)
|
2015-08-04 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
EP3331917A1
(en)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
|
BR112018002520A2
(pt)
|
2015-08-06 |
2018-09-18 |
Glaxosmithkline Ip Dev Ltd |
Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
|
|
WO2017021912A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combined tlrs modulators with anti ox40 antibodies
|
|
EP3331919A1
(en)
|
2015-08-07 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
|
ES2913208T3
(es)
|
2015-12-01 |
2022-06-01 |
Glaxosmithkline Ip Dev Ltd |
Tratamientos de combinación y usos y métodos de los mismos
|
|
JP6411676B2
(ja)
|
2015-12-03 |
2018-10-24 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Stingの調節因子としての環状プリンジヌクレオチド
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
IL280430B2
(en)
|
2016-03-18 |
2023-11-01 |
Univ Texas |
Cyclic dinucleotide compounds and methods of use
|
|
SG10201900628RA
(en)
|
2016-04-07 |
2019-02-27 |
Glaxosmithkline Ip Dev Ltd |
Heterocyclic amides useful as protein modulators
|
|
WO2017175156A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
CN109789135A
(zh)
|
2016-07-20 |
2019-05-21 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为perk抑制剂的异喹啉衍生物
|
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
EP3512842B1
(en)
|
2016-09-15 |
2024-01-17 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
CN109715163B
(zh)
|
2016-09-19 |
2022-11-22 |
诺华股份有限公司 |
包含raf抑制剂和erk抑制剂的治疗组合
|
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
IL325835A
(en)
|
2016-12-23 |
2026-03-01 |
Univ Yale |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
EP3582855A1
(en)
|
2017-02-15 |
2019-12-25 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
WO2018203219A1
(en)
|
2017-05-02 |
2018-11-08 |
Novartis Ag |
Combination therapy
|
|
CN110831582B
(zh)
|
2017-07-05 |
2023-08-11 |
诺华股份有限公司 |
药物组合物
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
UY37866A
(es)
|
2017-09-07 |
2019-03-29 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
US11377440B2
(en)
|
2017-10-05 |
2022-07-05 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING)
|
|
AU2018344902B2
(en)
|
2017-10-05 |
2021-06-03 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING) useful in treating HIV
|
|
WO2019106605A1
(en)
|
2017-12-01 |
2019-06-06 |
Board Of Regents, The University Of Texas System |
Combination treatment for cancer
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
EP3801069A4
(en)
|
2018-06-01 |
2022-03-16 |
Cornell University |
COMBINATION THERAPY FOR A PI3K-ASSOCIATED DISEASE OR DISORDER
|
|
WO2020030570A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
|
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
|
CA3106060A1
(en)
|
2018-08-07 |
2020-02-13 |
Metagone Biotech Inc. |
Ammonium salts of 3-(3,5-dibromo-4-hydroxybenzyliden)-5-indo-1,3-dihydroindol-2-one and uses thereof
|
|
KR102964218B1
(ko)
*
|
2018-09-18 |
2026-05-13 |
1글로브 바이오메디칼 씨오., 엘티디. |
비만의 치료
|
|
CN113613724B
(zh)
|
2018-11-30 |
2024-11-08 |
葛兰素史克知识产权开发有限公司 |
可用于hiv疗法的化合物
|
|
CN113795512A
(zh)
|
2019-02-01 |
2021-12-14 |
葛兰素史克知识产权开发有限公司 |
包含贝兰他单抗莫福汀和抗ox4抗体的癌症组合治疗及其用途和方法
|
|
EP4563150A3
(en)
|
2019-05-13 |
2025-07-23 |
Novartis AG |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
|
|
JP2022533390A
(ja)
|
2019-05-16 |
2022-07-22 |
スティングセラ インコーポレイテッド |
オキソアクリジニル酢酸誘導体および使用方法
|
|
US20220251079A1
(en)
|
2019-05-16 |
2022-08-11 |
Stingthera, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
|
CN113924114A
(zh)
|
2019-05-22 |
2022-01-11 |
吉利德科学公司 |
Tlr7调节化合物和hiv疫苗的组合
|
|
CA3143211A1
(en)
|
2019-06-26 |
2020-12-30 |
Glaxosmithkline Intellectual Property Development Limited |
Il1rap binding proteins
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
WO2021046293A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
WO2021119753A1
(en)
|
2019-12-18 |
2021-06-24 |
Ctxt Pty Limited |
Compounds
|
|
EP4096718A1
(en)
|
2020-01-28 |
2022-12-07 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
CN114573453B
(zh)
*
|
2020-12-02 |
2024-12-03 |
荆楚理工学院 |
一种选择性的羧酸酯裂解方法
|
|
EP4378478A4
(en)
|
2021-07-27 |
2025-11-12 |
Toray Industries |
MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
|
|
KR102566028B1
(ko)
*
|
2021-08-10 |
2023-08-10 |
계명대학교 산학협력단 |
신규한 다중 단백질 키나아제 억제제
|
|
CN114671887A
(zh)
*
|
2021-10-29 |
2022-06-28 |
四川大学华西医院 |
一种二氢吲哚酮类化合物的制备及其抗肿瘤应用
|
|
AR129423A1
(es)
|
2022-05-27 |
2024-08-21 |
Viiv Healthcare Co |
Compuestos útiles en la terapia contra el hiv
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|